TrialJournal of Crohn's & colitis2025

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.

Walter Reinisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.